What we know
The vaccine safety group says the “relatively few” reports of myocarditis “appear to be mild” and are below the expected baseline rates.
Among the cases, the heart condition appeared in adolescents and young adults, and more often in men than women. Symptoms typically appeared within four days after the second dose. Follow-up on the cases is ongoing, the work group said. Information about this potential adverse event should be provided to clinicians to enhance early recognition and appropriate management of persons who develop myocarditis symptoms following vaccination, the work group concluded.
What is myocarditis and what are the symptoms?
COVID-19 vaccine heart problems in teens, young adults: What we know azcentral.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from azcentral.com Daily Mail and Mail on Sunday newspapers.
NEW YORK â A team of researchers led by an Indian American scientist has reported the first instance of COVID-19 triggering a rare recurrence of potentially serious blood clots in patientsâ arms.
The discovery, published in the journal Viruses, improves the understanding of how inflammation caused by COVID can lead to upper extremity blood clots and how best to treat them.
While there have been reports of lower extremity deep vein thrombosis following COVID-19, this is the first study in which the disease triggered a recurrence in the upper arm of an active 85-year-old man who had a prior diagnosis of upper extremity blood clots.
Share this article
Share this article
NEW BRUNSWICK, N.J., May 19, 2021 /PRNewswire/ Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its cancer clinical research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8. A total of 16 presentations including 13 abstracts, two educational sessions and one clinical science symposium have been accepted, highlighting data in numerous types of cancer, including leukemia, lymphoma, melanoma and breast, lung and kidney cancer.